<DOC>
	<DOCNO>NCT00001644</DOCNO>
	<brief_summary>This study try define HIV infection persist body determine : 1 ) cell HIV live long period time without see destroy immune system ; 2 ) sit anti-HIV drug penetrate enough stop new HIV replication ; 3 ) HIV certain lymph node remain infectious prolong period time . It also explore whether immune system damage cause HIV repair new virus replication stop treatment . HIV-infected patient 18 year age old may eligible study , include three group follow . Candidates screen medical history , physical examination , blood urine test possibly chest X-ray electrocardiogram . Participants divide three group accord CD4 count level : &gt; 500 cells/microliter blood ; 300 500 cells/microliter , &lt; 300 cells/microliter blood . All participant treat combination four antiretroviral drug : indinavir , zidovudine , lamivudine nevirapine . ( Exceptions regimen may make certain circumstance patient tolerate one four drug . ) In addition , undergo follow procedure : Blood test - Blood test do screen study entry evaluate patient 's health status measure CD4 T cell count plasma HIV level ; begin treatment look drug-related side effect ; course study evaluate drug effectiveness inhibit HIV replication ; CD4 T cell level function . Lymph node biopsy - Lymph node biopsy do local anesthesia . A small incision make , node remove , incision close stitch . Up two node may remove procedure . Patients CD4 count great 500 cells/microliter blood count less 300 cells/microliter three lymph node biopsy order 1 ) ass effectiveness therapy inhibit HIV replication node ( major site replication ) ; 2 ) determine long HIV-infected cell may persist node new replication stop therapy ; 3 ) determine immune damage cause HIV repair virus replication stop . Lymph node biopsy patient count 300 500 cells/microliter blood require baseline , although follow-up biopsy encourage . Leukapheresis - In procedure , whole blood collect needle place arm vein . The blood circulates cell separator machine white cell remove collect . The rest blood return body , either needle use draw blood second needle place arm . The collected white cell use special study level function T cell drug treatment . Patients CD4 count &gt; 500 cells/microliter &lt; 300 cells/microliter undergo leukapheresis four time - study entry 2 , 6 12 month start antiretroviral therapy . Patients CD4 count 300 500 cells/microliter procedure either study entry 6 12 week initiation therapy , schedule patient .</brief_summary>
	<brief_title>Use Combined Antiretroviral Therapy Determine Sites Persistent HIV Infection</brief_title>
	<detailed_description>The reservoirs HIV-1 infection permit maintenance persistent virus infection ( even virus replication detect use sensitive assay quantify plasma HIV-1 RNA level ) currently unknown . Potential site persistent HIV-1 infection include cell chronic latent infection , cell present location within body antiviral drug may penetrate level sufficient prevent additional cycle de novo virus infection ( e.g. , central nervous system ) , presence susceptible target cell virus infection may metabolize certain antiviral drug active inhibitory form ( e.g. , macrophage ) , extracellular ( possible infectious ) virus may retain surface follicular dendritic cell within lymphoid organ . In attempt determine , , potential reservoir contribute persistent HIV-1 infection , HIV-1-infected person two group categorize CD4+ T cell level treat concomitant administration 4 antiviral drug ( zidovudine , lamivudine , indinavir nevirapine ) accomplish maximal achievable suppression virus replication . The rate decay virus virus-infected cell follow initiation antiviral ( steroid ) therapy monitor sensitive , quantitative assay , identity longevity persistent sit infection determine . This study may also illuminate extent HIV-1-induced immune system damage manifest decrease CD4 T cell response , constrict repertoire T cell antigen recognition , structural compromise lymphoid tissue architecture reverse upon cessation active HIV-1 replication combination potent antiviral drug .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>INCLUSION CRITERIA : Greater equal 18 year old . Ability sign inform consent willingness comply study requirement clinic policy . For woman childbearing potential , negative result pregnancy test within one week prior initiate therapy . No medical contraindication lymph node biopsy . HIV infection confirm ELISA Western blot . Two CD4+ T cell count less 300/microliters within 3 month begin protocol , one two count obtain screen history physical examination perform 2 week prior initiate therapy . Plasma HIV1 RNA level great 8000/ml . For participant CD4 T cell count great equal 300/microliter , asymptomatic significant HIVrelated illness . For participant CD4 T cell count less equal 300/microliter active opportunistic infection . For participant great equal 300 CD4 cells/ microliter , prior receipt antiretroviral therapy . For participant le equal 300 CD4 cells/microliter , prior use lamivudine , nevirapine protease inhibitor . Three palpable lymph node . Willingness allow storage sample future research . Willingness allow HLA test . EXCLUSION CRITERIA : Platelet count le 100,000 platelets/mm ( 3 ) . PT PTT ( absence document anticardiolipin antibody ) prolong great 2 second . Known underlie bleed disorder . Pregnancy breastfeed . Psychiatric illness might interfere study compliance . Active substance abuse history prior substance abuse may interfere protocol compliance compromise patient safety . Creatinine great 2 . Liver function test great 1.5 time normal laboratory value . Significant cardiac , pulmonary , kidney , rheumatologic , gastrointestinal , CNS disease detectable routine history , physical examination , screen laboratory study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 17, 2010</verification_date>
	<keyword>Immunodeficiency</keyword>
	<keyword>Latency</keyword>
	<keyword>T Cell Turnover</keyword>
	<keyword>Infected Cell Turnover</keyword>
	<keyword>Follicular Dendritic Cells</keyword>
</DOC>